ValiRx PLC Appointment of Director (3917R)
29 Junio 2020 - 5:44AM
UK Regulatory
TIDMVAL
RNS Number : 3917R
ValiRx PLC
29 June 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Appointment of Director
London, UK , 29 June 2020: ValiRx (AIM:VAL) announces that,
further to the announcement of 27 May 2020, Kevin Cox has been
appointed as Non-executive Chairman of the Company with effect from
26 June 2020.
The following information is disclosed in respect of Dr Kevin
Paul Cox (age 61) pursuant to Schedule 2(g) of the AIM Rules for
Companies:
Current directorships and partnerships Directorships and partnerships
held in the past five years
Aurora CBT Limited Bioindustry Association
-------------------------------
Biotaspheric Limited Imanova Limited
-------------------------------
Biorelate Limited Perenna Consulting Limited
-------------------------------
British Neuroscience Association
Limited
-------------------------------
The Griffin Practice Limited
-------------------------------
Mr Kevin Cox does not hold any ordinary shares nor options over
ordinary shares in the Company.
There is no further information which is required to be
disclosed under Schedule Two, paragraph (g) of the AIM Rules for
Companies in respect of Mr Kevin Cox.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 7073 2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469 0930
Duncan Vasey / Lucy Williams / Eran
Zucker
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer.
The Company's business model focuses on identifying and
in-licensing early stage projects, adding value through scientific
development and then out-licensing therapeutic candidates early in
the development process. By aiming for early-stage value creation,
the Company reduces risk while increasing the potential for
realising value.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFLFSIRFIAFII
(END) Dow Jones Newswires
June 29, 2020 06:44 ET (10:44 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024